These compounds operate through distinct mechanisms: DHC suppresses microglial activation [51], while TSN IIA has been shown to attenuate cancer‐induced bone pain in a dose‐dependent manner by suppressing spinal HMGB1‐mediated neuroinflammation—reflected by reduced IL‐1β, TNF‐α, and IL‐6 expression—and by inhibiting the hyperexcitability of wide dynamic range neurons in the deep dorsal horn, thereby diminishing both ongoing and breakthrough pain [52]. Here, HMGB1 is linked to cancer.